

Blocked-D phenomenon in hemolytic disease of fetus and newborn with multiple maternal anti-rhesus antibodies

Abstract

Background: The blocking of D antigen sites of RBC membrane of the fetus by the passively transferred IgG anti-D in cases of Hemolytic Disease of fetus and new born (HDFN) is called blocked- D phenomenon. The coating of maternal IgG type of anti-D prevents the agglutination of the Rh-(D) antigen positive red blood cells (RBC) by the IgM D-antigen typing reagents. We are reporting two cases of Rh-(D) HDFN which were falsely typed as Rh (D) antigen negative with routine typing reagents and had multiple allo-antibodies in the maternal serum.

Aims: To rule out HDFN and to confirm the Rh-(D) status of baby, to detect the presence of other allo-antibodies in the maternal serum that can complicate future transfusions in mother.

Materials: After routine blood grouping, sample of baby was subjected to adsorption-elution studies and maternal serum was used for antibody screening and identification

Results: In both the cases, blocked-D phenomenon got detected and there were multiple anti-rhesus antibodies other than anti-D in the maternal serum.

Conclusion: Antibody identification in antenatal women is important in the case management of HDFN to protect future pregnancies and to avoid the risk of mismatched transfusions.

Keywords: blocked-d phenomenon, HDFN, allo-antibodies, adsorption-elution, anti-D

Volume 7 Issue 2 - 2019

Anila Mani, Poornima AP, Debasish Gupta

Department of Transfusion Medicine, Sree Chitra Tirunal Institute for Medical Sciences and Technology, India

Correspondence: Dr. Debasish Gupta, Professor and Head, Department of Transfusion Medicine, SCTIMST, Medical College P. O. Thiruvananthapuram – 695011, Kerala, India
Email debasishgupta@gmail.com

Received: June 11, 2019 | **Published:** August 07, 2019

Abbreviations: RBC, red blood cells; CTT, conventional tube technique; CAT, column agglutination technology; IAT, indirect anti globulin test; DAT, direct anti-globulin test; HDFN, hemolytic disease of fetus and newborn

Introduction

The Rh blood group system consists of five important antigens D, C, c, E, and e. The D antigen is the most immunogenic of all the non-ABO antigens. Approximately 80% of individuals who are D-negative and exposed to a single D-positive unit will produce an anti-D antibody.¹ Hemolytic disease of fetus and newborn (HDFN) occurs when there is a destruction of fetal/neonatal red blood cells (RBC) by the trans-placentally obtained IgG antibodies produced by the mother. The blocking of D antigen sites of RBC membrane of the fetus by the passively transferred IgG anti-D in cases of HDFN is called blocked- D phenomenon. The coating of maternal IgG type of anti-D prevents the agglutination of the Rh-(D) antigen positive red blood cells (RBC) by the IgM D-antigen typing reagents. We are reporting two cases of Rh-(D) HDFN which were falsely typed as Rh (D) antigen negative with routine typing reagents and also had multiple allo-antibodies in the maternal serum.

Materials and methods

One EDTA and one clotted sample of the mother and the baby were obtained along with one EDTA sample of father and first child. Both the cases were referred from other hospitals. Blood group confirmation

was done by forward and reverse grouping (Conventional tube Technique or CTT). Direct Anti globulin test of the baby and Indirect Anti globulin test of maternal serum were carried out using both Conventional tube technique and Gel cards-Column Agglutination Technology or CAT (Ortho Biovue system Anti-IgG-c3d; Polyspecific coomb's card). Antibody screening and antibody identification were performed by CAT (Biorad ID Diapanel-P). Red cell elution was performed by Gentle heat elution technique at 45°C for 10minutes (Partial elution Technique).¹ Eluted red cells were tested for D antigen with three different types of monoclonal anti D (IgG, IgM, IgG-IgM blend). DAT was performed on eluted RBC to confirm complete elution of coated antibodies and the cells were Rh phenotyped. Adsorption was performed by Enzyme-treatment of RBC's using 1% Papain-cysteine. Antibody titration was done using Saline double dilution technique by CTT. Eluate was made to react with select cells by CAT (Ortho Biovue system Anti-IgG-c3d; Polyspecific coomb's card) for antibody identification and confirmation.

Case history

In the first case, a 27year-old lady G3P1L1A1 was admitted at 35weeks of gestation. Her blood group was A-Rh- (D) negative and first child A-Rh-(D) positive. She received Anti-Rh-(D) prophylaxis after the first delivery and abortion. No history of any previous blood transfusions. Indirect Anti globulin Test (IAT) was positive with a titre of 64 at 16weeks of gestation. From 24weeks, fetal anemia warranted four intrauterine transfusions. Last transfusion was given five days prior to delivery. Baby was delivered at 35weeks of gestation without

negative in the local hospital. Due to profound jaundice and signs of kernicterus, the baby was transferred to the neonatology department of higher centre. Despite three exchange transfusions with B RhD negative blood the Direct Anti globulin Test (DAT) remained positive and free anti-D was still detectable in the baby's serum. Anti-D with a titre of 32 was eluted from the baby's RBCs. Antenatal grouping and atypical antibody screening had not been performed.² This study shows that IgG anti-D need not be present in high titres to present with blocked D-phenomenon.

Verma and colleagues described a case of blocked D in RhD haemolytic disease of the fetus. At 20 weeks gestation, the maternal anti-D titre was found to be 256 by conventional tube technique. Subsequent ultrasound screening showed the fetus to be hydropic and percutaneous umbilical cord blood sampling confirmed fetal anemia (Hb 5.4g/dL and hematocrit 13.9%). The fetal RBC was grouped as RhD negative with a positive DAT, an eluate yielded anti-D, showing the D antigenic sites were blocked for the routine typing reagents to act. Successful intrauterine transfusion (IUT) was performed and post transfusion hemoglobin increased to 14.1g/dL and hematocrit 41.8%. An icteric baby was delivered, again grouping as RhD negative, but on this occasion due to the O-Rh-(D) negative blood used for the IUT.⁴

Yohannes and colleagues describes a case report in which after several transfusions with D-negative blood, an O Rh-D negative woman was apparently sensitized to the C and D antigens. In her prenatal workup, it became evident that she had in fact not been sensitized to D or C antigen as such but to G, which initially appeared as anti-D plus anti-C. Moreover, the fetus was affected significantly and was delivered at 32½ weeks with moderate hemolytic disease of the newborn.⁵ So, it is necessary to identify the presence of anti-G when the antibody identification shows reactivity pattern to both D and C antigens.

Hadley and colleagues in their study emphasizes the importance of continuous monitoring of C-antigen positive fetuses who were genotyped as D-negative when maternal serum apparently contains anti-C+D; HDFN due to anti-G may be of life-threatening severity and so it would seem advisable in such cases to test for anti-G in maternal serum.⁶ In cases where only anti-G is present; mother has to be given routine anti-D prophylaxis to protect future D antigen positive fetuses. Palfi and colleagues in their study had proposed that the G antigen seems to be highly immunogenic as anti-G occurred in 24 out of 27 patients compared to the occurrence of anti-D in 23 out of 27 patients in their study.⁷ Maley and colleagues mentions that cases where antibody identification reveals only anti- G, with or without anti-C, it is appropriate to administer anti-D immunoglobulin both during the pregnancy, and at the delivery of an RhD positive infant, to prevent the formation of anti-D.⁸

Moran and colleagues documents the natural history of anti-E HDFN in pregnancy and shows that a substantial proportion of infants are sufficiently affected by anti-E and they do suffer from clinically important HDFN. Twenty-one percent of affected infants received exchange transfusion and 10% had severe or very severe disease. The single, very severely affected case had a maximum anti-E titre of 1/1, highlighting the disparity between anti-E titre and disease severity.⁹

Markham and colleagues stated that the presence of multiple red blood cell antibodies is associated with increased odds for the development of significant HDFN. HDFN is more likely to occur in the presence of multiple red blood cell antibodies, especially in the presence of anti-(Rh) D. Heightened awareness of the increased

potential for significant HDFN in the presence of multiple red blood cell antibodies may prove to be helpful to the clinician, permitting anticipation and more aggressive antenatal management of these patients.¹⁰

While interpreting the results of blood grouping on fetal or neonatal samples from an allo immunized pregnancy with potent antibody, the blocking phenomenon should be taken into account. A false negative RhD grouping can be seen when maternal IgG antibodies saturate all antigen sites on fetal red cells and leave no antigen sites for the anti -D reagent to attach with. A proper clinical history, including the history of any intrauterine transfusions and results of previous immunohaematological investigations done during the perinatal period, is also very important in order to reach the final diagnosis.⁴ All women, regardless of their D type, should be tested during each pregnancy for clinically significant unexpected serum antibodies, ideally at their first visit to the obstetrician. Anti globulin testing should be done with anti- IgG to detect preferentially those antibodies with the potential to cross the placenta and cause HDFN.¹¹

Antibody identification in antenatal women are important for intrauterine transfusions also; since, always maternal allo-antibody need not be anti-D and it can be some other Rh and other minor blood group antibody which can complicate intrauterine transfusion. Usually O group Rh-(D) negative blood is preferred for intrauterine transfusion, but if the maternal antibody is other than anti-D and is against some other antigen present on the transfused O Rh-(D) negative red blood cells, then it will result in severe in-utero hemolytic disease of the fetus.

Conclusion

All cases of Rh-HDFN should not be merely considered to be due to anti-D. There can be coexistent other allo-antibodies contributing to it. Hence, proper identification of antibodies is as important as managing a case of HDFN to protect future pregnancies and to avoid the risk of mismatched transfusions.

Acknowledgments

We thank the Director, Sree Chitra Tirunal Institute for Medical Sciences and Technology and Department of Transfusion Medicine for permitting us to do the study. We also acknowledge Department of Pediatrics, SAT Hospital, Medical College, Trivandrum for providing blood samples for investigation.

Conflicts of interest

The author declares that there are no conflicts of interest.

References

1. Brecher ME. (American Association of Blood Banks) AABB Technical Manual. 15th ed. *Bethesda*: AABB; 2008.
2. Sulochana PV, Mathai AJ, Sathyabhama S, et al. Blocked D phenomenon, a rare condition with RhD haemolytic disease of newborn - a case report. *Int J Lab Hematol*. 2008;30:244-247.
3. Nicolaidis KH, Rodeck CH. Maternal serum anti-D antibody concentration and assessment of rhesus isoimmunisation. *BMJ*. 1992;304(6835):1155-1156.
4. Verma A, Sachan D, Bajpayee A, et al. RhD blocking phenomenon implicated for an immunohaematologic diagnostic dilemma in a case of RhD-haemolytic disease of fetus. *Blood Transfus*. 2013;11:140-142.

5. Yohannes W, Akhter JE. Hemolytic Disease of the Newborn Due to Anti-C and Anti-G Masquerading as Anti-D. *Am J Clin Pathol.* 1985;84(6):769–72.
6. Hadle AG, Poole GD, Poole J, et al. Haemolytic Disease of the Newborn Due to Anti-G. *Vox Sang.* 1996;71:108–12.
7. Palfi M, Gunnarsson C. The frequency of anti-C + anti-G in the absence of anti-D in allo immunized pregnancies. *Transfusion Medicine.* 2001;11(3):207–210.
8. Maley M, Babb R, Chapman CE, et al. Identification and quantification of anti-D,-C and -G in allo immunized pregnant women. *Transfusion Medicine.* 2001;11:443–446.
9. Moran P, Robson SC, Reid MM. Anti-E in pregnancy. *BJOG.* 2000;107:1436–1438.
10. Markham KB, Karen, Rossi BSN, et al. Hemolytic disease of the fetus and newborn due to multiple maternal antibodies. *Am J Obstet Gynecol.* 2015;213(1):68.e1–68.e5.
11. Judd JW. Practice guidelines for prenatal and perinatal immunohematology, revisited. *Transfusion.* 2001;41(11):1445–1452.